The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.
Hyo Song Kim
No relevant relationships to disclose
Han Sang Kim
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Hoon-Gu Kim
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
Jong-Seok Lee
No relevant relationships to disclose
Se-Hoon Lee
No relevant relationships to disclose
Kyung Hee Lee
No relevant relationships to disclose
Dae Joon Kim
No relevant relationships to disclose
Hye Ryun Kim
No relevant relationships to disclose
Joo-Hang Kim
No relevant relationships to disclose
Byoung Chul Cho
No relevant relationships to disclose